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Abstract
Objectives: In the early recognition of portal vein ligation (PVL) induced tumor progression, positron emission tomography
and magnetic resonance imaging (PET/MRI) could improve diagnostic accuracy of conventionally used methods. It is
unknown how PVL affects metabolic patterns of tumor free hepatic tissues. The aim of this preliminary study is to evaluate
the effect of PVL on glucose metabolism, using PET/MRI imaging in healthy rat liver.
Materials and Methods: Male Wistar rats (n = 30) underwent PVL. 2-deoxy-2-(18F)fluoro-D-glucose (FDG) PET/MRI imaging
(nanoScan PET/MRI) and morphological/histological examination were performed before (Day 0) and 1, 2, 3, and 7 days after
PVL. Dynamic PET data were collected and the standardized uptake values (SUV) for ligated and non-ligated liver lobes were
calculated in relation to cardiac left ventricle (SUVVOI/SUVCLV) and mean liver SUV (SUVVOI/SUVLiver).
Results: PVL induced atrophy of ligated lobes, while non-ligated liver tissue showed compensatory hypertrophy. Dynamic
PET scan revealed altered FDG kinetics in both ligated and non-ligated liver lobes. SUVVOI/SUVCLV significantly increased in
both groups of lobes, with a maximal value at the 2nd postoperative day and returned near to the baseline 7 days after the
ligation. After PVL, ligated liver lobes showed significantly higher tracer uptake compared to the non-ligated lobes
(significantly higher SUVVOI/SUVLiver values were observed at postoperative day 1, 2 and 3). The homogenous tracer
biodistribution observed before PVL reappeared by 7th postoperative day.
Conclusion: The observed alterations in FDG uptake dynamics should be taken into account during the assessment of PET
data until the PVL induced atrophic and regenerative processes are completed.
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Introduction
Despite advances in chemotherapy regimens and ablative
techniques, extended hepatectomy is considered as a gold standard
for the treatment of primary and secondary liver cancers. [1–3]
Nevertheless, surgical resection can be accomplished only in 20–
30% of the cases, due to insufficient amount of remaining liver
mass after hepatectomy (future remnant liver volume; FRLV). [4]
It is known for decades that occlusion of the portal vein results in
atrophy of the occluded liver lobe, while owing to the unique
regeneration capacity, the unoccluded liver tissue shows compen-
satory hypertrophy. [5] Based on this observation portal vein
occlusion techniques, such as portal vein ligation (PVL) or
embolization (PVE), have been introduced to increase the future
volume of the remnant liver before major liver resection. [6]
Considering that at the time of diagnosis most liver malignancies
show multiple bilateral patterns, a two-stage resection with portal
vein occlusion has recently been developed. During the first stage
of this novel treatment procedure, small metastasectomies in the
potential future remnant liver in combination with the occlusion of
the contralateral portal vein are performed with or without
chemotherapy. In the second curative stage, after compensatory
hypertrophy of cleared unoccluded lobes, the portal-deprived liver
lobes with residual tumors are removed. [7].
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Although, the above detailed two-stage procedure is more
widely used, there is increasing evidence that PVL/PVE-induced
changes have a strong stimulatory effect on tumor growth as well.
Thus, there might be an increased risk, that portal vein occlusion
could stimulate not only the growth of future remnant liver, but
also significantly affects tumor size and tumor spread in both
occluded and non-occluded liver segments. [8] Several clinical and
preclinical studies have demonstrated the increased proliferative
activity of malignant cells after preoperative portal vein occlusion.
[9–11] Tumor progression in the liver between the time of PVL/
PVE and the next phase of hepatectomy is responsible for the
majority of changes into irresectable state which occurs in
approximately 20% of the cases of planned for two-stage surgeries.
[12,13].
The average time to achieve optimal FRLV (optimal time of the
second, curative operation) is approximately 1 month after PVL/
PVE. [14] During this waiting period, the monitoring of
regenerative process and tumor progression are essential. In a
clinical scenario, computed tomography (CT) is currently the gold-
standard method of assessing the increase in FRLV. [15]
However, CT volumetry may not be reliable in the detection of
residual tumor growth, because the accuracy of CT is poor for
smaller (,0.2–1 cm) tumor sizes. [16] MRI, especially with liver-
specific contrast agents, could improve the sensitivity by providing
better soft-tissue contrast, but is not sufficiently specific leading to
number of false positive lesions. [17] These drawbacks of
morphological imaging techniques indicate the importance of
additional functional imaging assays, which could more specifically
recognize tumor progression during two-stage hepatectomy
combined with portal vein ligation.
In clinical oncology positron emission tomography (PET) is an
extremely valuable tool for tumor diagnosis, staging, restaging and
for treatment response follow-up. [18] To image hepatic neoplasia
several PET radiopharmaceuticals are available, such as [11C]-
acetate, [11C]-choline and 2-deoxy-2-(18F)fluoro-D-glucose (FDG).
In the oncologic use of PET, however, FDG is the most commonly
used tracer, which is able to assess the typically enhanced glucose
transport and metabolism in malignant tumors. FDG was found to
be superior in detecting residual tumor growth and tumor
recurrence compared to morphologic imaging procedures, fur-
thermore, FDG-PET is the primary imaging modality for
detection of distant (extrahepatic) metastasis. [19] Although,
FDG is an excellent tracer in case of tumor localization, it is not
tumor specific. [20] Increased FDG uptake was observed in several
energy-intensive processes such as inflammation, as well as during
regeneration. The regenerative and atrophic process induced by
the ligation/embolization of portal vein is associated with not only
volumetric, but also with hemodynamic and metabolic changes.
[21] These complex alterations after PVL/PVE may also affect
the FDG uptake patterns of tumor free hepatic tissues, which
constitute a challenge in the differentiation of these processes from
intrahepatic tumor spread. Therefore, unfolding the changes
regarding FDG uptake after PVL/PVE in a tumor free, healthy
liver is essential in the early recognition of tumor progression.
There is no study in the literature that assesses the changes in
FDG uptake pattern of normal liver after PVL/PVE. Kinetic
FDG data combined with volumetric information available from
MR imaging of the liver, are more reliable than PET alone or
PET/CT. Thus, the aim of our present study was to selectively
evaluate dynamics of FDG uptake in occluded and non-occluded
liver lobes by in vivo multimodal FDG PET-MRI (nanoScan
PET/MRI) in a well-established rat model of portal vein ligation.
Materials and Methods
Portal Vein Ligation (PVL)
The experimental design was regulated in strict adherence to
the National Institutes of Health guidelines for animal care and
approved by Committee on Animal Experimentation of Semmel-
weis University (permit number: 22.1/2408/3/2011 and XIV-I-
001/29-7/2012). 200–250 g male Wistar rats (Charles River
Hungary Ltd., Budapest, Hungary) were kept on standard chow
and water ad libitum in specific, pathogen-free conditions at 22–
24uC with a 12-hour light-dark cycles. Animals were allowed to
acclimatize for 1 week before starting experiments. After intra-
peritoneal injection of ketamine (75 mg/kg) and xylazine (7.5 mg/
kg), animals were placed in a supine position and median
laparotomy was performed. The median and left lateral lobes
were gently mobilized to reveal the portal pedicels. Under
operating microscope (Zeiss Opmi Surgical Microscope, Carl
Zeiss Meditec AG, Jena, Germany) the portal branches feeding the
median, left lateral and caudate lobes (approximately 80% of total
liver mass) were dissected and completely ligated with 6–0 silk.
Great care was taken to avoid damaging the vulnerable hepatic
artery and bile duct. At the end of the procedure the liver lobes
were gently repositioned anatomically, the peritoneal cavity was
closed in two layers by running suture (4–0) and the animals were
returned to their cages until further examination. Before (0 day)
and 1, 2, 3, 7 days after portal vein ligation, rats were sacrificed by
exsanguination for histological analysis. The liver was removed
and the ligated and non-ligated lobes were weighted separately
after expulsion of blood by gentle compression with gauze. Liver
specimens were taken from the excised left lateral lobe (ligated
lobe) and the superior right lobe (non-ligated lobe). Samples were
fixed in 4% neutral-buffered formalin and embedded in paraffin
for further histological and immunohistochemical examination
(see below). At each time point, six animals were used (n= 6; in all
n = 30).
Positron Emission Tomography/Magnetic Resonance
Imaging (PET/MRI)
In a separate study additional 6 animals underwent imaging
12 hours before and 1, 2, 3 and 7 days after portal vein ligation.
Images were acquired with a PET/MRI (nanoScan PET/MRI,
Mediso Ltd., Hungary) sequential animal imaging system. Blood
glucose levels were confirmed to be within the normal range
before injection of the radioactive tracer and throughout the study.
In the PET experiment 6.561.0 MBq of FDG in 0.2 mL volume
was injected into the tail vein, under anesthesia (2% isoflurane in
100% O2 gas). To prevent movement, the animals were fixed to a
rat chamber (MultiCell Imaging Chamber, Mediso Ltd., Hungary)
and positioned in the center of field of view (FOV). Dynamic list-
mode PET data were collected in three-dimensional acquisition
mode. The MRI images (matrix size 1406140; 0.5 mm; 30 slices;
1.3 mm; gap 0.5 mm) were acquired for 50 minutes (25 minutes
for each imaging) with T1-weighted (SE2D; TR/TE 800/10 ms;
FOV 70 mm; NEX 4), T2-weighted (FSE2D; TR/TE 4733/
60 ms; FOV 70 mm; NEX 2) sequences. PET volumes were
reconstructed using a three-dimensional Ordered Subsets Expec-
tation Maximization (3D-OSEM) algorithm (Tera-Tomo, Mediso
Ltd., Hungary) into dynamic frames of 10630 s, 10660 s,
106270 s (total 60 min, 30 frames) for all scans with a voxel size
of 0.3 mm. Static images were generated based on frame 21 (15th
to 19th minutes were integrated after tracer injection). PET and
MRI images were automatically coregistered by the PET/MRI
instrument’s acquisition software. Reconstructed, reoriented and
coregistered images were further analyzed with Fusion (Mediso
PET/MRI Measurements in Healthy Liver after PVL
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Ltd., Hungary) and VivoQuant (inviCRO LLC, US) dedicated
image analysis softwares by placing appropriate Volume of
Interests (VOI) on the organs. Two volume of interests were
delineated manually slice by slice on each T1 weighted scans. One
VOI consisted of the ligated liver lobes and the other of the non-
ligated liver lobes. For volumetric analysis the built-in VOI
statistics of the VivoQuant software was used, which determines
the volume from voxel size and number of voxels in the VOIs. In
order to get more precise values of the volumes, the T1 weighted
slices were interpolated through the slice direction to create an
isovoxel data set. For FGD uptake, the standardized uptake value
(SUV) was calculated by dividing the mean radioactivity
concentration (MBq/mL) by injected dose per body weight
(MBq/g). The mean SUV for ligated and for non-ligated liver
lobes were selectively recorded. The mean SUV of corresponding
liver lobes was expressed in relation to a reference tissue SUV
(cardiac left ventricle; SUVVOI/SUVCLV) and to the mean liver
SUV (SUVVOI/SUVLiver).
Evaluation of Liver Regeneration and Atrophy
Liver lobe wet weight was measured separately after exsangui-
nations using a laboratory scale (Mettler Toledo AG 245, Mettler-
Toledo LLC, Columbus, OH, readability: 0.01 mg/0.1 mg). The
relative weight of ligated and non-ligated lobes to the body weight
(BW) was then calculated and expressed as follows: liver weight
(g)/100 g BW. The liver volume change was measured by MRI
and the relative liver volume was expressed as mm3/100 g BW.
The change in liver volume calculated from PET/MRI was
compared with the results derived from autopsy.
Histological and Immunohistochemical Examination
After liver weight measurement, one slice was removed for
pathological examination from the same anatomic position in each
animal. The formalin fixed, paraffin embedded 3–5 micrometer
thick sections underwent light microscopic observation after
hematoxylin and eosin staining. Necrosis was assessed by morpho-
logical features (swollen cytoplasm, vacuolization, disrupted cell
and organelle membranes and lytic nuclear changes) on each
section. The extent of necrosis was graded on a scale of 0–4
described by Suzuki [22]: grade 0– absence of necrosis; grade 1–
single cell necrosis; grade 2–30% lobular necrosis; grade 3–60%
lobular necrosis; grade 4– more than 60% lobular necrosis.
Hepatocyte apoptotic cell death was identified also by morphological
criteria (cell shrinkage, chromatin condensation, margination and
apoptotic bodies) and was counted in 10 consecutive high-power
fields (HPF, x200) and expressed in absolute numbers.
For the detection of mitotic activity Ki-67 immunohistochemical
staining was applied on formalin-fixed, paraffin-embedded tissues.
Avidin–biotin–peroxidase complex immunohistochemical method
was performed for antigen retrieval. [23] Primary antibodies were
MIB-5 antibody against Ki-67 (DAKO, Glostrup, Denmark) of
hepatocytes. Labeling index was defined as the mean number of
Ki-67-positive cells per HPF (6200), respectively.
To determine cellular glycogen content, periodic acid and Schiff
(PAS) staining was used. The intensity of PAS staining was graded
on a five tier scale (0: no staining –5: highly intense). The level of
glycogen content was determined by scoring at least three
independent microscopic fields for each sample.
The above mentioned histological and immunohistochemical
evaluations were performed in blinded fashion by two experienced
pathologists.
Statistical Analysis
Mann–Whitney U test and two sample Student t-test were used
to compare data between groups. Normality was tested by
Kolmogorov-Smirnov test. Correlation between variables was
tested by Spearman’s method. All tests were performed using the
Statistical Package for Social Sciences (IBM SPSS Statistics 20.0
software, IBM Corporation, Armonk, NY, USA). Values are
expressed as means 6 S.D. A p,0.05 confidence interval was
considered as statistically significant.
Results
Liver Hypertrophy and Atrophy Induced by Portal Vein
Ligation
The weight of the portal-deprived lobes decreased rapidly after
the operation and reached approximately one-fourth its original
weight on postoperative day 7. On the other hand the non-ligated
liver lobes underwent compensatory gain in weight. By a balance
of atrophy and hypertrophy, the weight of total liver was
maintained near to the baseline throughout the entire experiment.
The volume of liver lobes changed in parallel with the liver
weights. The volume change, based on MRI volumetry, correlated
well with the weight change derived from autopsy (r = 0.842; p,
0.001); (Figure 1.).
Histomorphological Characteristics of Ligated and Non-
ligated Liver Lobes
Atrophy of portal-deprived liver lobes was mainly caused by the
combination of necrosis and apoptosis. Extensive coagulation
necrosis occurred in the central zone of liver lobules one day after
the ligation. The necrotic areas became significantly reduced in
size at postoperative day 2 and 3. At this time, a high number of
macrophages were observed in the necrotic region. Seven days
after the operation necrosis could not be observed, while the
normal hepatic architecture recovered, with no signs of fibrosis.
The number of apoptotic hepatocytes also increased rapidly after
the operation and reached the peak on postoperative day 2.
Apoptosis was most frequently present at the boundary between
necrotic and non-necrotic areas and remained elevated until the
7th postoperative day. In contrast, in the non-ligated liver lobes,
the presence of necrosis and apoptosis was not typical (Figure 2.
A–B).
To examine proliferating capacity of the liver Ki-67 immuno-
histochemical staining was performed. Ki-67 is expressed by
proliferating cells in late G1, S, G2 and M phases, however it is
absent in the resting, G0 phase, therefore it is a reliable marker to
detect mitotic activity. With this immunohistochemical staining,
increased mitotic activity was found in non-ligated lobes with the
peak response at 2nd days. Thereafter, the number of positive cells
decreased and reached the baseline level at 7th postoperative day.
However, in the ligated liver lobes the number of Ki-67 positive
cells did not change significantly during the experiment (Figure 2.
C–D).
Liver showed a moderate, homogeneous glycogen staining
before (day 0) PVL. Day 1 after ligation, PAS positive glycogen
granules almost completely disappeared in ligated lobes and the
glycogen content of cells returned to baseline level just at day 7. In
contrast, the PAS staining in non-ligated liver lobes did not show
significant alterations compared to the baseline level (day 0) in any
examined time point (Figure 3).
PET/MRI Measurements in Healthy Liver after PVL
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18F-FDG Data Analysis
Dynamic PET scans revealed an altered FDG kinetics
characterized by prolonged tracer elimination in both ligated
and non-ligated liver lobes. The alterations in time activity curves
of ligated lobes were more remarkable compared to the non-
ligated lobes (Figure 4.). Before PVL the liver showed homogenous
tracer biodistribution. After PVL, FDG uptake within the liver
shifted towards the ligated lobes. The SUVVOI/SUVCLV showed a
significantly increased FDG uptake in ligated liver lobes. That
value was maximal on 2nd postoperative day and returned near to
the baseline at the 7th day. In non-ligated lobes the SUVVOI/
SUVCLV also increased, but in a significantly lower extent
compared to the ligated lobes. The increment in FDG uptake of
non-ligated lobes reached a statistically significant level on 2nd and
3rd postoperative day only, as compared to the baseline (Figure 5.).
SUVVOI/SUVLiver in ligated lobes significantly increased com-
pared to that in non-ligated liver lobes with the maximal level on
2nd postoperative day. Then at 7th postoperative day the SUVVOI/
SUVLiver returned to baseline levels and the lobes of liver showed
again similar FDG uptake pattern (Figure 6. A–B).
Discussion
In the recent years two-stage hepatectomy with portal vein
ligation became widely used to surgically treat large primary or
secondary liver tumors. However portal vein occlusion not only
induces liver regeneration, but also potentially results in loco-
regional or metastatic tumor spread, making liver resection
difficult. [9] In the early recognition of postoperative tumor
progression (regional and distant metastases alike), the anatomic
information derived from conventional CT or MRI can be
insufficient, thus the introduction of functional imaging assays is
required to improve diagnostic accuracy. However, to draw
adequate conclusion from PET studies, exploring the alteration in
tracer kinetics in normal, tumor free liver tissues after PVL is
necessary.
In our experiment PET/MRI was used to evaluate the PVL
induced alterations in the FDG uptake in parallel with the change
in volume of ligated and non-ligated liver lobes in healthy rats. In
our study, PVL induced volume and weight changes in liver mass,
that are typical in such cases. [5] The ligated liver lobes underwent
a massive atrophic process, while the non-ligated lobes showed
compensatory hyperplasia. As a result the total liver mass was
unchanged throughout the entire experiment. This progressive
volumetric alteration was completed by postoperative day 7.
In parallel to the volume changes, dynamic PET data revealed
altered FDG kinetics in both the ligated and non-ligated liver lobes
after PVL. To accurately determine the alteration in FDG uptake,
mean SUV of liver lobes were compared to a reference image
derived from the blood input of the left cardiac ventricle.
SUVVOI/SUVCLV highly significantly increased in ligated lobes,
while in the non-ligated lobes just a moderate increase was
observed. The different FDG uptake of the ligated and non-ligated
lobes was more obvious, when the SUV of corresponding lobes
was compared to the whole liver radioactivity concentration.
Before PVL, the liver showed homogenous FDG distribution.
Figure 1. Changes in weight and volume of the liver after portal vein ligation. A: The macroscopic appearance of liver by post mortem
examinations and three dimensional MRI reconstruction preoperatively (0), as well as 1, 2, 3 and 7 days after portal vein ligation (PVL). Changes in
weight (B) and volume (C) of total liver, ligated and non-ligated liver lobes at the examined time points. The alteration in liver weight showed a
significant positive correlation with the volume change (r = 0.842, P,0.001; tested by Spearman’s method). Values are expressed as mean6 S.D. Each
column represents the average of 6 animals. a = superior right lateral lobe; b = inferior right lateral lobe; c = median lobe; d = left lateral lobe.
doi:10.1371/journal.pone.0090760.g001
PET/MRI Measurements in Healthy Liver after PVL
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After PVL, the SUVVOI/SUVLiver significantly elevated in the
ligated lobes compared to that in the non-ligated part of liver. The
contrast between the lobes was the most significant at postoper-
ative day 2. Thereafter, by the postoperative 7th day, when the
PVL induced volumetric alterations were completed, the pre-PVL
FDG uptake pattern returned and the lobes of liver showed again
similar tracer biodistribution.
To explore the cause of these altered FDG uptake pattern,
histological examinations were performed. Our results suggest that
two main processes could be responsible for the remarkable
elevated FDG accumulation in ligated lobes:
(1) The atrophy of portal deprived liver lobes is mainly caused by
coagulation necrosis, as a result of the cessation of portal
vascular inflow and the consequent hypoxic condition around
the central vein. [24] The reduction in the numbers of the
viable cells through necrosis should be reflected by decreased
FDG uptake. [25] However, in the ligated lobes increased
FDG accumulation was detected, for which some energy-
intensive processes surrounding these necrotic lesions may
Figure 2. Histomorphological characteristics of the liver after portal vein ligation. A: Histomorphological characteristics of the ligated
lobes 1 day after portal vein ligation (PVL). Wide necrotic areas were seen around the central vein. At the boundary between the necrotic and non-
necrotic areas (white line) apoptosis was frequently present (black arrows). B: The extent of necrotic areas and the number of apoptotic cell death
significantly increased in ligated lobes compared with that seen in non-ligated liver lobes. C: Ki-67 labeling in non-ligated lobes on 2nd day after
surgery. Ki-67 antibody reacts with the nuclear structure present exclusively in the proliferative phase of the cell cycle. In the non-ligated liver lobes
immunohistochemistry (brown stain) show a high expression level of Ki-67 in cell nuclei, which represent an increased mitotic activity of the
hepatocytes. D: Mitotic activity of hepatocytes significantly increased in non-ligated liver lobes, with the peak response on day 2. In contrast, the Ki-67
positivity of ligated lobes did not change significantly throughout the experiment. Values are expressed as mean 6 S.D. Each column presents the
average of 6 animals. PV = portal vein; CV= central vein; * = p,0.05 versus non-ligated lobes; #= p,0.05 versus ligated lobes.
doi:10.1371/journal.pone.0090760.g002
Figure 3. Glycogen content of cells. Glycogen content of ligated
lobes (striped column) decreased markedly after portal vein ligation and
it reached the baseline level at postoperative day 7. In non-ligated lobes
(black column), the PAS staining did not show any significant alteration
throughout the experiment. Values are expressed as mean 6 S.D. Each
column represents the average of 6 animals. * = p,0.05 versus the
baseline level (0 day) of the corresponding lobes.
doi:10.1371/journal.pone.0090760.g003
PET/MRI Measurements in Healthy Liver after PVL
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responsible. (A) Apoptosis: At the boundary between necrotic
and non-necrotic areas, a large number of apoptotic cells were
found. It is well-documented, that apoptosis is an energy-
intensive process, because adenosine-triphosphate (ATP) is
required for the activation of the efferent molecules of caspase
family. However, in these areas around the necrotic fields, a
moderate degree of hypoxia is still present. [26] The limited
ability of oxygen leads to anaerobic glycolysis, a less efficient
use of glucose, with increased necessity of glucose extraction
from blood, which consequently could lead to enhanced FDG
uptake of the apoptotic cells, and could be reflected in the
PET scan. [27–29] (B) Inflammation: Besides apoptosis, a
massive inflammatory reaction was also present around the
necrotic regions in the slides. At postoperative day one,
macrophages appeared at the rim of the necrotic areas and
began to remove the debris. Activated macrophages are
characterized with high glucose turnover and consequently
increased FDG uptake. [30] It should be noted that, the above
detailed histological alterations showed considerable individ-
ual variation on first 3 postoperative days, when the atrophic
process was the most intensive. This variability also reflected
in PET data, which is characterized by a significant deviation
during this period.
(2) The decreased FDG release from hepatocytes- caused by the
elevated glycogenolysis – can also contribute to the increased
FDG accumulation in the ligated liver lobes. FDG is a glucose
analog, which is normally trapped inside the cells after
phosphorylation as FDG-6-phosphate. However, in the liver,
FDG-6-phosphate is dephosphorylated and rapidly released,
presumably due to the high activity of glucose-6-phosphatase
(G-6-Pase). [31] In our experiment an abrupt loss of liver
glycogen was observed in the portal deprived liver lobes,
which suggests that the ligated lobes may take part in
maintaining blood glucose level by accelerated glycogenolysis
after PVL. Although, the extent of glycogenolysis is elevated
after PVL, the enzyme activity of G-6-Pase of ligated liver
Figure 4. Time activity curves of ligated and non-ligated lobes at different time points. After portal vein ligation (PVL) the characteristics
of curves showed altered tracer kinetics in both ligated (gray; dotted line) and non-ligated (black; solid line) liver lobes, but these changes in ligated
lobes were more pronounced. The most significant alterations can be seen on 2nd postoperative day, then 7 days after the operation the curves
characteristic showed similar appearance to the pre-PVL data.
doi:10.1371/journal.pone.0090760.g004
PET/MRI Measurements in Healthy Liver after PVL
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lobes are shown to be unaltered. [32][33] The elevated
glycogenolysis and the unchanged G-6-Pase activity of the
ligated liver lobes, might result in the intracellular accumu-
lation of glucose-6-phosphate, which is capable to inhibit the
dephosphorylation, thereby the release of FDG-6-phosphate
by competing for the catalytic unit of G-6-Pase.
In non-ligated liver lobes FDG uptake also increased, but to a
significantly lower extent than in ligated lobes, despite the presence
of massive regeneration characterized by high mitotic activity of
cells. Cell division would supposedly be associated with high
glucose/FDG-uptake. [34] However, literature data demonstrated
that glucose is not the primary energy source of regeneration in the
liver. Already in early phase of regeneration the hepatic
metabolism is shifted from carbohydrates utilization to the
consumption of lipids. [35] Consistent with this, Brinkmann et al
showed that after partial hepatectomy intracellular concentrations
of glucokinase decreased to less than one third within the first
72 hours. [36] Given that the level of active glucokinase is a
determining factor in FDG uptake, the altered glycolytic activity of
hepatocytes during liver regeneration could explain why FDG
uptake increased just moderate level in non-ligated liver lobes,
despite the significant mitotic activity. Another explanation for
moderate FDG uptake in the non-ligated lobes might lie in the
high portal glucose supply of liver. Rocheleau et al showed a
230% increase in flow of non-ligated lobes after PVL and 96% of
this flow is derived from the portal vein. [37] Taking into account
that the portal vasculature receives three times more glucose per
minute than the hepatic artery, the glucose supply of the
regenerating liver mass is abundant. [38] However, the high
plasma glucose levels can inhibit FDG uptake by competing for
the binding site of the hepatic glucose transporter proteins. [39]
This competition between plasma glucose and FDG could result in
the moderate-level of FDG uptake observed in non-ligated,
regenerating liver lobes by PET scan.
The above detailed alteration in FDG uptake pattern could
have a significant impact on the evaluation of PET studies after
PVL. The increased FDG accumulation, especially in the case of
ligated lobes, could make difficult the assessment of tumor
progression by increased background activity until the PVL
induced alterations are completed. However, it also should be
noted that, the alteration in FDG uptake of non-ligated lobes was
moderate and reached significant level only at the 2nd and 3rd
postoperative days. This lower-grade lobar FDG activity might
make possible the early recognition of residual tumorous lesions in
non-ligated liver shortly after the operation. Considering that, in
terms of treatment decision, the critical points are the tumor
progression in the future remnant liver (non-ligated lobes) or the
formation of distant metastases, the use of FDG-PET/MRI could
be beneficial in the early assessment of tumor response to PVL.
Figure 5. The ratio of mean SUV of ligated and non-ligated
lobes to cardiac left ventricle SUV. The FDG uptake significantly
increased in ligated (striped column) liver lobes, with maximal value on
2nd postoperative day and returned to near to the baseline 7 day after
portal vein ligation. In non-ligated (black column) lobes the tracer
uptake also increased, but significantly lower extent compared to the
ligated lobes. Values are expressed as mean 6 S.D. Each column
represents the average of 6 animals. * = p,0.05 versus the baseline
level (0 day) of the corresponding lobes;#= p,0.05 versus non-ligated
lobes; ##= p,0.01 versus non-ligated lobes.
doi:10.1371/journal.pone.0090760.g005
Figure 6. Tracer biodistribution in ligated and non-ligated liver lobes. A:Representative coregistered PET and MRI image of rat liver before
(top) and 3 days after (bottom) portal vein ligation (PVL). The PET reconstruction is based on frame 21 (at 15–19 minutes). The top inset picture shows
a homogeneous liver FDG uptake pattern in both liver lobes. The small inhomogeneity is related to the morphology of liver. After PVL the liver shows
inhomogeneous tracer distribution with significantly increased FDG uptake in ligated lobes, while the tracer uptake in cardiac left ventricle (*) remain
constant. B: The ratio of mean SUV of ligated (striped column) and non-ligated (black column) liver lobes to mean liver SUV. The SUVVOI/SUVLiver
significantly increased in ligated liver lobes compared to the non-ligated lobes after PVL with the peak response on day 2. Values are expressed as
mean 6 S.D. Each column represents the average of 6 animals. ** = p,0.01 versus non-ligated lobes.
doi:10.1371/journal.pone.0090760.g006
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Nevertheless, our study has some limitations. The main
limitation is the use of normal, healthy liver. In a clinical scenario,
the primary and secondary liver tumors usually appear in cirrhotic
or fatty livers, in which circumstances the PVL induced alterations
and consequently the imaging characteristics of liver lobes may
vary. Furthermore, this study examined only tumor-free animals,
however, the altered circumstances caused by PVL may result in
alteration of tumor FDG uptake as well. Further research on
tumor-bearing animals is needed to evaluate this potential tumor
response regarding to FDG-uptake after PVL. Finally, it should be
noted that FDG is appropriate for the diagnosis only of FDG
positive tumors. However, some liver cancer, such as hepatocel-
lular carcinoma is characterized by variable FDG uptake caused
by the variation in the expression of G-6Pase. In such case, the
results from FDG-PET/MRI could become uncertain, therefore
more specific tracers, such as [11C]-acetate should be used. [40].
Conclusion
The aim of the study was to evaluate the FDG uptake pattern in
healthy liver after PVL in small animals. Our result showed an
altered FDG uptake pattern in both ligated and non-ligated liver
lobes after PVL. These alterations in FDG uptake should be taken
into account during the assessment of PET data until the PVL
induced atrophic and regenerative processes are completed.
Because this initial study merely examined healthy animals,
further preclinical and clinical studies are needed to define the
impact of FDG-PET in therapeutic follow-up after a two stage-
hepatectomy combined with PVL.
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